Lycorine Induces Apoptosis of A549 Cells via AMPK-Mammalian Target of Rapamycin (mTOR)-S6K Signaling Pathway

Background: This study was designed to investigate the effect of lycorine (LY) on the AMPK-mTOR-S6K signaling pathway and to clarify its role in autophagy and apoptosis.

Material/Methods: Various concentrations of LY were used to treat non-small cell lung carcinoma A549 cells. The MTT assay was used to measure cell viability and acridine orange staining was used to detect cell morphology changes. Western blot analysis was used to test the effect of LY on the expression levels of LC3, caspase 3, and other proteins involved in the AMPK-mTOR-S6K signaling pathway.

Results: The half maximal inhibitory concentration (IC50) of LY after 24-h treatment was 8.5 μM, with stronger inhibitory effect of 24-h LY treatment over 12-h LY treatment. Morphological observation showed that lower doses (4 μM and 8 μM) of LY treatment induced A549 cell death mainly caused by autophagy, whereas the higher dose (16 μM) of LY treatment induced A549 cell death, mainly caused by apoptosis. Furthermore, 8 μM LY caused the highest conversion of LC3-II from LC3-I. All LY treatments activated caspase-3. LY treatment also promoted AMPK phosphorylation (Thr172) and inhibited the phosphorylation of mTOR and S6K.

Conclusions: LY induced apoptosis of A549 cells by regulating the AMPK-mTOR-S6K signaling pathway. Lower levels (4~8 μM) of LY-induced autophagy contributed to LY-induced apoptosis.

MeSH Keywords: Apoptosis • Autophagy • MAP Kinase Signaling System

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/900742
MOLECULAR BIOLOGY

Background

Lung cancer is one of the malignant tumors with highest incidence and mortality. Clinical surgery and radiotherapy and chemotherapy are less effective for patients with advanced lung cancer. With the development of traditional Chinese medicine (TCM), it has become an effective method for the treatment of lung cancer [1]. Natural medicine has become one of the main sources of anti-cancer drugs because of its rich resources and a variety of pharmacological effects. Lycoris (LY) is an isoquinoline alkaloid isolated from bulbs of Monocotyledones amaryllidaceae plants. Recent studies have shown that LY (chemical structure shown in Figure 1) can be used in treatment of viral infection [2,3], inflammation [4], malaria [5], osteoporosis [6], and cancer [7].

During autophagy, the cell’s own proteins and organelles are swallowed into vesicles and combined with lysosomes to form autophagic lysosomes to degrade the contents and provide material and energy required for cell metabolism. Autophagy helps to maintain cell viability, but excessive autophagy may cause cell death. During tumorigenesis, autophagy regulates cell survival and death [8]. Apoptosis is programmed cell death, which maintains cell homeostasis [9,10]. Autophagy has been reported to be closely associate with apoptosis: (1) autophagy is one of the upstream processes required for apoptosis, and inhibition of autophagy can effectively inhibit apoptosis [11]; (2) autophagy can reduce the rate of apoptosis via inhibition of apoptosis [12]; and (3) autophagy and apoptosis can synergistically promote cell death [13], and regulation of both autophagy and apoptosis can switch between these 2 kinds of death [14]. Therefore, the effect of drugs on the regulation of autophagy and apoptosis of tumor cells is particularly important.

AMPK are kinases present in eukaryotic cells and they regulate energy metabolism. Inhibition of AMPK activity may effectively activate mTOR, thereby regulating cell growth and metabolism [15]. In situations of low blood sugar, hypoxia, and other stress conditions, the AMP/ATP ratio rises to activate AMPK α subunit, the latter in conjunction with the kinase LKB1 promotes phosphorylation in Thr172 [16, 17]. Phosphorylation of AMPK activates the tuberous sclerosis complex (TSC), thereby inhibiting downstream substrates of mammalian target of rapamycin (mTOR) [18]. Reports in the literature indicate that the AMPK-mTOR-S6K signaling pathway is closely linked to autophagy and apoptosis. Research in mammalian systems found that inhibition of mTOR activated autophagy [19]. In addition, AMPK can change the conformational of pro-apoptotic protein Bax to maintain mitochondrial transmembrane potential (ΔΨm), blocking the release of cytochrome C and activation of caspase-3, which in turn inhibits apoptosis [20].

In the present study, human lung adenocarcinoma A549 cells were used as research subjects, and the commonly used anti-cancer drugs cisplatin and curcumin were included [21–23] as positive controls to explore the effect of LY on the autophagy and apoptosis of A549 cells to provide a scientific basis for new ideas and directions for the clinical treatment of lung cancer.

Material and Methods

Material

Lycorine (purity >98%) was obtained from Nanjing Purun Tech Co. and cisplatin (purity >98.5%) was obtained from Dalian Meilun Biotech. Curcumin (purity >98%) was purchased from Shanghai Jianglai Biotech and non-small cell lung cancer cell line A549 was from Nanjing Lishizi Biotech (Nanjing, China). Fetal bovine serum was purchased from Hyclone (Logan City, UT). DMEM were from Shanghai Feli i Biotech (Shanghai, China). Cell culture flasks, cell culture dishes, and 96- and 6-well plates were purchased from Tianjin Ruishina biotech (Tianjin, China). MTT and trypsin was bought from Nanjing Zhongshan Biotech (Nanjing, China). Wortmannin was purchased from Selleck (Houston, TX). Protein extraction kit and BCA protein quantification kit were from Shijiazhuang Haisen Chemical (Shijiazhuang, China). Mouse anti-human β-actin (Item No. 3700), rabbit anti-human AMPK (Item No 5831), rabbit anti-human mTOR (Item No. 2983), rabbit anti-human S6K (Item No. 2708), rabbit anti-human LC3 (Item No. 3868), rabbit anti-human caspase3 (Item No. 9662), rabbit anti-human phosho AMPK (Item No. 5256), and rabbit anti-human S6K (Item No. 9234) antibodies were bought from Cell Signaling Technology (Danvers, MA). Goat anti-rabbit IgG-HRP (sc-2004) and goat anti-mouse IgG-HRP (sc-2005) secondary antibodies were from Santa Cruz Biotechnology (Dallas, TX).

Methods

MTT assay

LY was dissolved in DMSO (≥99%) and diluted in DMEM medium. A549 cells were inoculated at a concentration of 3000/well...
into 96-well plates. Various concentrations of LY solution (0.5 μM, 1 μM, 2 μM, 4 μM, 8 μM, 16 μM, and 32 μM) were added into cell culture medium and cultured at 37°C for 12 h (A) or 24 h (B) for analysis of cell viability by MTT assay. LY – Lycorine; Cis – cisplatin; Cur – curcumin. * P<0.05, compared with curcumin group and cisplatin group.

**Figure 2.** Effects of 3 compounds on cell viability of A549 cells. A549 cells were inoculated in 96-well plates followed by addition of different concentrations of LY solution (0.5 μM, 1 μM, 2 μM, 4 μM, 8 μM, 16 μM, and 32 μM) and then cultured at 37°C for 12 h (A) or 24 h (B) for analysis of cell viability by MTT assay. LY – Lycorine; Cis – cisplatin; Cur – curcumin. * P<0.05, compared with curcumin group and cisplatin group.

Morphology observation

A549 cells were inoculated into 6-well plates at a density of 3×10^4/mL. Various concentrations of LY (0.5 μM, 1 μM, 2 μM, 4 μM, 8 μM, 16 μM, and 32 μM) were added and the cells were cultured for 24 h. Acidine orange (final concentration of 1 μg/mL) was used to stain the cells for 15 min, and the cells were observed under a fluorescence microscope. There were 3 control groups: 4 μM and 8μM of lycorine and 100 nM autophagy inhibitors wortmannin were simultaneously added to the culture medium and incubated for 24 h, or cells were treated with 16 μM of LY for 24 h, then 100 nM wortmannin was added.

Western blot detection of protein expression

Cells were pelleted and RIPA buffer was used to lyse the cells. Protein concentrations were measured by use of a BCA protein quantification kit. We loaded 20 μg of each sample and resolved it by SDS-PAGE. Proteins were then transferred to PVDF membranes. After blocking (5% skim milk) for 2 h, anti-LC3, caspase3, AMPK, mTOR, S6K, phosphor-AMPK, phosphor-mTOR, phosphor-S6K, and β-actin antibodies (1: 1000) were added and incubated at 4°C overnight. After washing with TBST 3 times, horseradish peroxidase-conjugated secondary antibody (1: 5000) was added and incubated at 37°C for 2 h. After washing, ECL was used to develop it in a gel imaging system (GE, ImageQuant, model LAS4000). Image J software (National Institutes of Health, Bethesda, MA) was used to quantify the bands.

Statistical analysis

All data were analyzed using GraphPad prism5.0 statistical software (Ventura, CA). Data are expressed as means ± SD, differences between groups were analyzed by ANOVA or t-test, and P <0.05 was considered statistically significant.

**Results**

**Lycorine inhibited A549 proliferation**

MTT assay results showed that the survival rate of A549 cells decreased with the increase of concentration and treatment time of LY, indicating that LY dose- and time-dependently suppressed A549 cell activity. IC50 of 12-h LY treatment and 14-h LY treatment were 27 μM and 8.5 μM, respectively, which was much better than that of curcumin (12 h and 24 h of IC50 >32 μM), and comparable with that of cisplatin (12 h and 24 h of IC50, 24 μM and 7.5 μM) (Figure 2).

**Lycorine promoted autophagy**

Acridine orange can stain cytoplasm and nuclei to dark red and bright green, and stains acidic vesicles to bright red. In late autophagy, autophagic vacuoles combine with acidic
lysosomes to form autophagy lysosomes; therefore, acridine orange stained acidic vesicles can be used as one of the signs of late autophagy. Wortmannin, as a PI3K kinase inhibitor, can inhibit early autophagy. Acridine orange staining results showed that compared with controls, low-dose (1 and 2 μM) LY treatment did not significantly induce morphology changes (Figure 3A–3C). Medium-dose (4–8 μM) LY treatment resulted in cytoplasmic vacuolization and increase of acidic vesicles but no significant change of the nucleus (Figure 3D, 3E), and 100 nM wortmannin treatment effectively reduced the number of acidic vesicles (Figure 3G, 3H). Nuclear condensation was caused by 16 μmol/L of LY treatment (Figure 3C–3F) but 100 nM wortmannin treatment did not induce further morphology change (Figure 3C–3I). These data suggested that at certain concentrations (from 0 to 8 μM), autophagy was increased with the increase of LY concentration. When LY concentration reached 16 μM, the cells began to show morphology changes and apoptosis.

Figure 3. Morphology changes of A549 cells induced by LY (acridine orange staining). A549 cells were inoculated into 6-well plates followed by addition of different concentrations of LY and cultured for 24 h. Acridine orange (final concentration of 1 μg/mL) was used to stain the cells for 15 min, and the cells were observed under a fluorescence microscope (×200). (A) 0 μM LY; (B) 1 μM LY; (C) 2 μM LY; (D) 4 μM LY; (E) 8 μM LY; (F) 16 μM LY; (G) 4 μM LY with 100 nM wortmannin; (H) 8 μM LY with 100 nM wortmannin; (I) 16 μM LY for 24 h, then added 100 nM wortmannin.
**Effect of LY on the expression levels of autophagy- and apoptosis-related proteins**

Western blot results showed that the levels of LC3-II were increased along with the increase of LY concentration and reached the highest level at LY concentration of 8 μM, indicating that LY promoted autophagy. The ratio of LC3-II and LC3-I was lower at 16 μM LY. The levels of caspase-2 were increased along with the increase of LY concentration and reached the highest level at an LY concentration of 16 μM. These results suggested that low-dose LY (<8 μM) stimulated autophagy of A549 cells, and a high concentration of LY (>16 μM) caused apoptosis of A549 cells (Figure 4).

**LY effect on AMPK, mTOR, and S6K**

Western blot results showed that increased LY concentration caused increased phosphorylation of AMPK but decreased phosphorylation of mTOR and S6K in Ser2481 and Thr389, suggesting that LY promoted phosphorylation of AMPK to suppress the phosphorylation of mTOR and S6K to inhibit cell proliferation and stimulate autophagy (Figure 5).

**Discussion**

Autophagy and apoptosis play important roles in the maintenance of normal body functions. Induction of apoptosis of tumor cells is used for cancer treatment. The resistance of tumor cells in the treatment process is the main factor restricting anti-tumor therapy. As another type of programmed cell death, autophagy has become a popular new focus in cancer therapy. Excessive autophagy can promote cell apoptosis. It has been shown that ionizing radiation can induce autophagy in human breast cancer cells, and promote the progression of apoptosis [28]. In our study, we found that low concentrations of LY increased the ratio of LC3-II/LC3-I. The 8-μM LY treatment showed the highest ratio of LC3-II/LC3-I. Higher concentration of LY (>8 μM) decreased the ratio of LC3-II/LC3-I. Caspase-3 is a member of the cysteine-aspartic protease family, which is generally considered a marker of the apoptosis signaling pathway. In normal cells, caspase-3 is mainly presented as an inactive zymogen (Pro-caspase-3) form. In the process of

![Figure 4](image-url). Effect of 24-h LY treatment on LC3 and caspase-3. A549 cells were inoculated into 6-well plates followed by addition of various concentrations of LY and cultured for 24 h. Then proteins were extracted for analysis of expression of LC3 and caspase-3 by Western blot. (A) Effect of 24-h LY treatment on LC3 (B) Effect of 24-h LY treatment on caspase-3. * P<0.05, compared with the control group; * P<0.05, compared with the 8 μmol/L LY group.
apoptosis, Pro-caspase-3 is hydrolyzed at Asp28~Ser29 and Asp175~Ser176 to form P17 (29~175) and P10 (182~277) fragments. The latter 2 can re-organize together to form caspase-3, which promotes the implementation of the apoptosis pathway. We found that caspase-3 was activated by LY treatment in a dose- and time-dependent manner. Thus, we believe that the low concentration of LY treatment (24 h) induced autophagy of A549, but the high concentrations of LY treatment (24 h) promoted apoptosis of A549 cells.

The results of this experiment showed that LY treatment of A549 cells for 24 h enhanced the phosphorylation of AMPK at Thr172 in a dose-dependent manner. Phosphorylation of AMPK can significantly reduce the activity of mTOR (Ser2481) and S6K (Thr389), thereby blocking downstream signaling. Inhibition of mTOR activity also promoted autophagy. The inhibitory effect of LY on A549 cell viability was stronger than that of curcumin (12 and 24 h IC50 >32 μM), and was comparable to that of cisplatin (12 and 24 h IC50: 24, 7.5 μM). These data suggest that within a certain range of concentrations and treatment times, LY-induced autophagy can promote apoptosis of A549 cells, primarily by enhancing AMPK activity and suppressing phosphorylation of mTOR and S6K.

**Conclusions**

Lycorine inhibited A549 cells proliferation by enhancing activation of AMPK and suppressing the mTOR-S6K signaling pathway. Lower concentrations of LY (4~8 μmol/L) can activate autophagy, and a higher concentration of LY (16 μmol/L) can induce apoptosis. These results provide a scientific basis for studying the effect of LY on tumor cell death, the relationship between autophagy and apoptosis, and the use of autophagy enhancers or inhibitors in cancer therapy.

**Disclosure of conflict of interest**

None.
References:

1. Xue D, Han S, Jiang S et al: Comprehensive geriatric assessment and traditional Chinese medicine intervention benefit symptom control in elderly patients with advanced non-small cell lung cancer. Med Oncol, 2015; 32: 114

2. Guo Y, Wang Y, Cao L et al: A conserved inhibitory mechanism of a lycorine derivative against enterovirus and hepatitis C virus. Antimicrob Agents Chemother, 2015; 60: 913–24

3. Chen D, Cai J, Cheng J et al: Design, synthesis and structure-activity relationship optimization of lycorine derivatives for HCV inhibition. Sci Rep, 2015; 5: 14972

4. Shen JW, Ruan Y, Ren J et al: Lycorine: A potential broad-spectrum agent against crop pathogenic fungi. J Microbiol Biotechnol, 2014; 24: 354–58

5. Kuger S, Corek E, Polat B et al: Novel PI3K and mTOR inhibitor NVP-BEZ235 radiosensitizes breast cancer cell lines under normoxic and hypoxic conditions. J Microencapsul, 2016; 33(3): 274–85

6. Kiliçay E, Karahaliloglu Z, Hazer B et al: Concanavaline A conjugated bacterial polymer-based PHBHxx nanoparticles loaded with curcumin for breast cancer therapy. J Microencapsul, 2016; 33(3): 274–85

7. Liu X, Sun K, Wang H, Dai Y: Knockdown of retinoblastoma protein may sensitize glioma cells to cisplatin through inhibition of autophagy. Neurosci Lett, 2016; 620: 393–410

8. Li J, Gao Y, Ren J et al: Metformin protects against cisplatin-induced tubular cell apoptosis and acute kidney injury via AMPKalpha-regulated autophagy induction. Sci Rep, 2016; 6: 23975

9. Lee K, Hong S, Seong GJ, Kim CY: Cigarette smoke extract causes injury in primary renal ganglion cells via apoptosis and autophagy. Curr Eye Res, 2016; 4: 1–6

10. Chen X, Tan M, Xie Z et al: Inhibiting ROS-STAT3-dependent autophagy enhanced capsaicin-induced apoptosis in human hepatocellular carcinoma cells. Free Radic Res, 2016; 50(7): 1–31

11. Lin CY, Hsu SC, Lee HS et al: Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberosic sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure. J Vasc Surg, 2013; 57: 475–85

12. Sanii T, Steinberg GR, Singh G, Taksiridis T: AMP-activated protein kinase (AMPK) beyond metabolism: A novel genomic stress sensor participating in the DNA damage response pathway. Cancer Biol Ther, 2014; 15: 156–69

13. Han D, Li S, Zhu Y et al: LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer. Asian Pac J Cancer Prev, 2013; 14: 4033–39

14. Cardnell RJ, Feng Y, Mukherjee S et al: Activation of the PI3K/mTOR pathway following PARP inhibition in small cell lung cancer. PLoS One, 2016; 11: e0152584

15. Zeng H. et al.: Enhanced capsaicin-induced apoptosis in human hepatocellular carcinoma cell A549. Zhongguo Zhong Yao Za Zhi, 2015; 40: 3278–82

16. Wu GQ, Chai KQ, Zhu XM et al: Anti-cancer effects of curcumin on lung cancer through the inhibition of EZH2 and NOTCH1. Oncotarget, 2016; 7(18): 26535–50

17. Aoki H, Takada Y, Kondo S et al: Evidence that curcumin suppresses the growth of malignant gliomas in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo. Sci Rep. 2015; 5: 12853

18. Kilicay E, Karahaliloglu Z, Hazer B et al: Concanavaline A conjugated bacterial polymer-based PHBHxx nanoparticles loaded with curcumin for breast cancer therapy. J Microencapsul, 2016; 33(3): 274–85

19. Bollu VS, Barui AK, Mondal SK et al: Curcumin-loaded silica-based mesoporous materials: Synthesis, characterization and cytotoxic properties against cancer cells. Mater Sci Eng C Mater Biol Appl, 2016; 63: 393–410

20. Jia YL, Li J, Qin ZH, Liang ZQ: Autophagic and apoptotic mechanisms of curcumin-induced death in K562 cells. J Asian Nat Prod Res, 2009; 11: 918–28

21. Xu D, Han S, Jiang S et al: Comprehensive geriatric assessment and traditional Chinese medicine intervention benefit symptom control in elderly patients with advanced non-small cell lung cancer. Med Oncol, 2015; 32: 114

22. Guo Y, Wang Y, Cao L et al: A conserved inhibitory mechanism of a lycorine derivative against enterovirus and hepatitis C virus. Antimicrob Agents Chemother, 2015; 60: 913–24

23. Chen D, Cai J, Cheng J et al: Design, synthesis and structure-activity relationship optimization of lycorine derivatives for HCV inhibition. Sci Rep, 2015; 5: 14972

24. Shen JW, Ruan Y, Ren J et al: Lycorine: A potential broad-spectrum agent against crop pathogenic fungi. J Microbiol Biotechnol, 2014; 24: 354–58

25. Kuger S, Corek E, Polat B et al: Novel PI3K and mTOR inhibitor NVP-BEZ235 radiosensitizes breast cancer cell lines under normoxic and hypoxic conditions. Breast Cancer (Auckl), 2014; 8: 39–49

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)